Can you delay Alzheimer’s? How a new dementia screening test and drug may help
On World Alzheimer’s Day, we examine how a timely diagnosis can prepare someone with early dementia, and the pros and cons of a new drug
If a treatment were available, a significant majority of people would get tested for dementia, says charity Alzheimer’s Disease International (ADI).
ADI, based in London in the UK, works with dementia and Alzheimer’s associations in more than 100 countries. It asked a lot of people the testing question: 40,000 in 166 countries.
Hamid Sohrabi is a professor of psychology and clinical neuroscience at Murdoch University in Australia and director of its Centre for Healthy Ageing; he and his team recently developed the McCusker Subjective Cognitive Impairment Inventory (McSCI-S) – a screening test for dementia risk.
The McSCI-S has been translated and is in its final stage of being released for clinical and research applications in China.
The questionnaire collects information about how a person perceives the changes in their cognitive abilities and whether these changes affect their daily functioning, Sohrabi says.
